{"id":30759,"date":"2023-12-21T13:41:24","date_gmt":"2023-12-21T18:41:24","guid":{"rendered":"https:\/\/www.cancerresearch.org\/?post_type=cri_news&#038;p=30759"},"modified":"2023-12-21T13:46:31","modified_gmt":"2023-12-21T18:46:31","slug":"cri-ceo-and-director-of-scientific-affairs-dr-jill-odonnell-tormey-on-immunotherapy-and-her-tenure","status":"publish","type":"cri_news","link":"https:\/\/www.cancerresearch.org\/es\/media-room\/cri-ceo-and-director-of-scientific-affairs-dr-jill-odonnell-tormey-on-immunotherapy-and-her-tenure","title":{"rendered":"CRI CEO and Director of Scientific Affairs Dr. Jill O\u2019Donnell-Tormey on Immunotherapy and Her Tenure"},"content":{"rendered":"\n<p>NEW YORK \u2013 Jill O\u2019Donnell-Tormey, PhD, CEO and director of scientific affairs at the Cancer Research Institute (CRI), recently sat down with <em>Inside Precision Medicine <\/em>to discuss a wide variety of topics \u2013 her career at CRI, the organization\u2019s progress in the last 70 years, and the current state of immunotherapy, among others.\u00a0<\/p>\n\n\n\n<p>Dr. O\u2019Donnell-Tormey began the interview by discussing CRI\u2019s robust, 70-year history at the forefront of cancer immunotherapy research. Shortly thereafter, she transitioned to talking about her tenure as the CEO of CRI for 30 years, and how the organization has, in her words, kept the field of cancer immunotherapy research alive. She expressed pride in how CRI has trained multiple generations of immunologists.&nbsp;<\/p>\n\n\n\n<p>Dr. O\u2019Donnell-Tormey discussed the critical importance of checkpoint blockades to the field of cancer immunotherapy research and emphasized that cancer immunotherapy is a multifaceted discipline, and how important it is to utilize various immunotherapies along with other standard therapies like chemotherapy or radiation to provide precise treatment to patients. &nbsp;<\/p>\n\n\n\n<p>Additionally, she elaborated on the importance of the multiple clinical trials that CRI is involved with, specifically regarding pancreatic and lung cancers. Further, Dr. O\u2019Donnell-Tormey explained that CRI\u2019s Scientific Advisory Council helps facilitate the organization\u2019s academic partnerships through open access to the application process.&nbsp;<\/p>\n\n\n\n<p>We hope you find Dr. O\u2019Donnell-Tormey\u2019s interview to be equally informative and interesting. To read it in full, visit <em><a href=\"https:\/\/www.insideprecisionmedicine.com\/topics\/oncology\/in-conversation-with-cris-jill-odonnell-tormey-phd\/\">Inside Precision Medicine<\/a>.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK \u2013 Jill O\u2019Donnell-Tormey, PhD, CEO and director of scientific affairs at the Cancer Research Institute (CRI), recently sat down with Inside Precision Medicine to discuss a wide variety of topics [&hellip;]<\/p>\n","protected":false},"featured_media":30353,"template":"","tags":[18,26,32,101],"resource_cancer_types":[],"resource_patient_age":[],"resource_cancer_stage":[],"resource_treatment_type":[],"resource_treatment_status":[],"class_list":["post-30759","cri_news","type-cri_news","status-publish","has-post-thumbnail","hentry","tag-cancer-awareness","tag-checkpoint-inhibitors","tag-clinical-trials","tag-patient-education"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CRI CEO and Director of Scientific Affairs Dr. Jill O\u2019Donnell-Tormey on Immunotherapy and Her Tenure - Cancer Research Institute<\/title>\n<meta name=\"description\" content=\"CRI CEO and Director of Scientific Affairs Dr. Jill O&#039;Donnell-Tormey participated in an interview about CRI, immunotherapy, and her tenure.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cancerresearch.org\/media-room\/cri-ceo-and-director-of-scientific-affairs-dr-jill-odonnell-tormey-on-immunotherapy-and-her-tenure\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CRI CEO and Director of Scientific Affairs Dr. Jill O\u2019Donnell-Tormey on Immunotherapy and Her Tenure - Cancer Research Institute\" \/>\n<meta property=\"og:description\" content=\"CRI CEO and Director of Scientific Affairs Dr. Jill O&#039;Donnell-Tormey participated in an interview about CRI, immunotherapy, and her tenure.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cancerresearch.org\/media-room\/cri-ceo-and-director-of-scientific-affairs-dr-jill-odonnell-tormey-on-immunotherapy-and-her-tenure\" \/>\n<meta property=\"og:site_name\" content=\"Cancer Research Institute\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-21T18:46:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/11\/MicrosoftTeams-image-12-1024x1024.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/cri-ceo-and-director-of-scientific-affairs-dr-jill-odonnell-tormey-on-immunotherapy-and-her-tenure\",\"url\":\"https:\/\/www.cancerresearch.org\/media-room\/cri-ceo-and-director-of-scientific-affairs-dr-jill-odonnell-tormey-on-immunotherapy-and-her-tenure\",\"name\":\"CRI CEO and Director of Scientific Affairs Dr. Jill O\u2019Donnell-Tormey on Immunotherapy and Her Tenure - Cancer Research Institute\",\"isPartOf\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/cri-ceo-and-director-of-scientific-affairs-dr-jill-odonnell-tormey-on-immunotherapy-and-her-tenure#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/cri-ceo-and-director-of-scientific-affairs-dr-jill-odonnell-tormey-on-immunotherapy-and-her-tenure#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/11\/MicrosoftTeams-image-12.png\",\"datePublished\":\"2023-12-21T18:41:24+00:00\",\"dateModified\":\"2023-12-21T18:46:31+00:00\",\"description\":\"CRI CEO and Director of Scientific Affairs Dr. Jill O'Donnell-Tormey participated in an interview about CRI, immunotherapy, and her tenure.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/cri-ceo-and-director-of-scientific-affairs-dr-jill-odonnell-tormey-on-immunotherapy-and-her-tenure#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cancerresearch.org\/media-room\/cri-ceo-and-director-of-scientific-affairs-dr-jill-odonnell-tormey-on-immunotherapy-and-her-tenure\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/cri-ceo-and-director-of-scientific-affairs-dr-jill-odonnell-tormey-on-immunotherapy-and-her-tenure#primaryimage\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/11\/MicrosoftTeams-image-12.png\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/11\/MicrosoftTeams-image-12.png\",\"width\":2395,\"height\":2395},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/cri-ceo-and-director-of-scientific-affairs-dr-jill-odonnell-tormey-on-immunotherapy-and-her-tenure#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cancerresearch.org\/es\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Media Room Article\",\"item\":\"https:\/\/www.cancerresearch.org\/media-room\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"CRI CEO and Director of Scientific Affairs Dr. Jill O\u2019Donnell-Tormey on Immunotherapy and Her Tenure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cancerresearch.org\/#website\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"name\":\"Cancer Research Institute\",\"description\":\"For a World Immune to Cancer\",\"publisher\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cancerresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\",\"name\":\"Cancer Research Institute\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"width\":156,\"height\":53,\"caption\":\"Cancer Research Institute\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CRI CEO and Director of Scientific Affairs Dr. Jill O\u2019Donnell-Tormey on Immunotherapy and Her Tenure - Cancer Research Institute","description":"CRI CEO and Director of Scientific Affairs Dr. Jill O'Donnell-Tormey participated in an interview about CRI, immunotherapy, and her tenure.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cancerresearch.org\/media-room\/cri-ceo-and-director-of-scientific-affairs-dr-jill-odonnell-tormey-on-immunotherapy-and-her-tenure","og_locale":"es_ES","og_type":"article","og_title":"CRI CEO and Director of Scientific Affairs Dr. Jill O\u2019Donnell-Tormey on Immunotherapy and Her Tenure - Cancer Research Institute","og_description":"CRI CEO and Director of Scientific Affairs Dr. Jill O'Donnell-Tormey participated in an interview about CRI, immunotherapy, and her tenure.","og_url":"https:\/\/www.cancerresearch.org\/media-room\/cri-ceo-and-director-of-scientific-affairs-dr-jill-odonnell-tormey-on-immunotherapy-and-her-tenure","og_site_name":"Cancer Research Institute","article_modified_time":"2023-12-21T18:46:31+00:00","og_image":[{"width":1024,"height":1024,"url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/11\/MicrosoftTeams-image-12-1024x1024.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cancerresearch.org\/media-room\/cri-ceo-and-director-of-scientific-affairs-dr-jill-odonnell-tormey-on-immunotherapy-and-her-tenure","url":"https:\/\/www.cancerresearch.org\/media-room\/cri-ceo-and-director-of-scientific-affairs-dr-jill-odonnell-tormey-on-immunotherapy-and-her-tenure","name":"CRI CEO and Director of Scientific Affairs Dr. Jill O\u2019Donnell-Tormey on Immunotherapy and Her Tenure - Cancer Research Institute","isPartOf":{"@id":"https:\/\/www.cancerresearch.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cancerresearch.org\/media-room\/cri-ceo-and-director-of-scientific-affairs-dr-jill-odonnell-tormey-on-immunotherapy-and-her-tenure#primaryimage"},"image":{"@id":"https:\/\/www.cancerresearch.org\/media-room\/cri-ceo-and-director-of-scientific-affairs-dr-jill-odonnell-tormey-on-immunotherapy-and-her-tenure#primaryimage"},"thumbnailUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/11\/MicrosoftTeams-image-12.png","datePublished":"2023-12-21T18:41:24+00:00","dateModified":"2023-12-21T18:46:31+00:00","description":"CRI CEO and Director of Scientific Affairs Dr. Jill O'Donnell-Tormey participated in an interview about CRI, immunotherapy, and her tenure.","breadcrumb":{"@id":"https:\/\/www.cancerresearch.org\/media-room\/cri-ceo-and-director-of-scientific-affairs-dr-jill-odonnell-tormey-on-immunotherapy-and-her-tenure#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cancerresearch.org\/media-room\/cri-ceo-and-director-of-scientific-affairs-dr-jill-odonnell-tormey-on-immunotherapy-and-her-tenure"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/media-room\/cri-ceo-and-director-of-scientific-affairs-dr-jill-odonnell-tormey-on-immunotherapy-and-her-tenure#primaryimage","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/11\/MicrosoftTeams-image-12.png","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2023\/11\/MicrosoftTeams-image-12.png","width":2395,"height":2395},{"@type":"BreadcrumbList","@id":"https:\/\/www.cancerresearch.org\/media-room\/cri-ceo-and-director-of-scientific-affairs-dr-jill-odonnell-tormey-on-immunotherapy-and-her-tenure#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cancerresearch.org\/es"},{"@type":"ListItem","position":2,"name":"Media Room Article","item":"https:\/\/www.cancerresearch.org\/media-room"},{"@type":"ListItem","position":3,"name":"CRI CEO and Director of Scientific Affairs Dr. Jill O\u2019Donnell-Tormey on Immunotherapy and Her Tenure"}]},{"@type":"WebSite","@id":"https:\/\/www.cancerresearch.org\/#website","url":"https:\/\/www.cancerresearch.org\/","name":"Cancer Research Institute","description":"For a World Immune to Cancer","publisher":{"@id":"https:\/\/www.cancerresearch.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cancerresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cancerresearch.org\/#organization","name":"Cancer Research Institute","url":"https:\/\/www.cancerresearch.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","width":156,"height":53,"caption":"Cancer Research Institute"},"image":{"@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_news\/30759","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_news"}],"about":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/types\/cri_news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media\/30353"}],"wp:attachment":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media?parent=30759"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tags?post=30759"},{"taxonomy":"resource_cancer_types","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_cancer_types?post=30759"},{"taxonomy":"resource_patient_age","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_patient_age?post=30759"},{"taxonomy":"resource_cancer_stage","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_cancer_stage?post=30759"},{"taxonomy":"resource_treatment_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_treatment_type?post=30759"},{"taxonomy":"resource_treatment_status","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_treatment_status?post=30759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}